Bard adds breast care to offerings with $213m SenoRx buy
This article was originally published in Clinica
Executive Summary
CR Bard is to expand its peripheral vascular business beyond ultrasound-guided products with a definitive agreement to buy breast cancer diagnosis and treatment specialist SenoRx for $213m.